Richard G. Vile

18.4k citations

278 papers · 13.7k indexed · h-index 67

Genetics top 0.05%
- Virus-based gene therapy research 189
Oncology top 0.2%
- CAR-T cell therapy research 102
Biotechnology top 0.1%
- Cancer Research and Treatments 43
Immunology top 0.5%
- Immunotherapy and Immune Responses 78
Infectious Diseases top 0.5%
- Viral gastroenteritis research and epidemiology 44
Molecular Biology
- RNA Interference and Gene Delivery 53
- Viral Infectious Diseases and Gene Expression in Insects 31
- CRISPR and Genetic Engineering 21

Co-authors: Alan Melcher Kevin J. Harrington Hardev Pandha Rosa María Díaz Ian R. Hart Jill Thompson Timothy Kottke Stephen J. Russell
Cited by: Genetics Oncology Biotechnology
Partner nations: United States United Kingdom Canada

In The Last Decade

Richard G. Vile

273 papers receiving 13.4k citations

Peers

Countries citing papers authored by Richard G. Vile

Since Specialization

Citations

This map shows the geographic impact of Richard G. Vile's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard G. Vile with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard G. Vile more than expected).

Fields of papers citing papers by Richard G. Vile

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard G. Vile. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard G. Vile. The network helps show where Richard G. Vile may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Richard G. Vile, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard G. Vile Line = papers co-authored together Richard G. Vile links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression Zachariah P. Tritz,Katayoun Ayasoufi,Delaney M. Wolf,Carley A. Owens,Courtney S. Malo,Benjamin Himes,Cori E. Fain,Emma N. Goddery,Lila T. Yokanovich,Fang Jin,Michael J. Hansen,Ian F. Parney,Chensu Wang,Kelly D. Moynihan,Darrell J. Irvine,K. Dane Wittrup,Rosa M. Diaz Marcano,Richard G. Vile,Aaron J. Johnson	2023	1
2	Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cells Marco Künzli,Stephen D. O’Flanagan,Madeleine LaRue,Poulami Talukder,Thamotharampillai Dileepan,J. Michael Stolley,Andrew G. Soerens,Clare F. Quarnstrom,Sathi Wijeyesinghe,Yanqi Ye,Justine S. McPartlan,Jason S. Mitchell,Christian W. Mandl,Richard G. Vile,Marc K. Jenkins,Rafi Ahmed,Vaiva Vezys,Jasdave S. Chahal,David Masopust	2022	45
3	Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies Victoria Roulstone,David Mansfield,R. J. C. Harris,Katie Twigger,Christine White,Johann S. de Bono,James Spicer,Sophia N. Karagiannis,Richard G. Vile,Hardev Pandha,Alan Melcher,Kevin J. Harrington	2021	10
4	Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer Eva Crespo-Rodriguez,Katharina Bergerhoff,Galabina Bozhanova,Shane Foo,Emmanuel C. Patin,Harriet Whittock,Richard Buus,Syed Haider,Gareth Muirhead,Khin Thway,Kate Newbold,Robert S. Coffin,Richard G. Vile,Dae Joon Kim,Martin McLaughlin,Alan Melcher,Kevin J. Harrington,Malin Pedersen	2020	24
5	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment Laura Evgin,Amanda L. Huff,Timothy Kottke,Jill Thompson,Amy M. Molan,Christopher B. Driscoll,Matthew Schuelke,Kevin G. Shim,Phonphimon Wongthida,Elizabeth J. Ilett,Karen Kaluza Smith,Reuben S. Harris,Matt Coffey,José S. Pulido,Hardev Pandha,Peter J. Selby,Kevin J. Harrington,Alan Melcher,Richard G. Vile	2019	13
6	Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer Nicola Annels,David Mansfield,Mehreen Arif,Carmen Ballesteros‐Merino,Guy R. Simpson,Mick Denyer,Sarbjinder Sandhu,Alan Melcher,Kevin J. Harrington,B. Davies,Gough G. Au,Mark Grose,Izhar Bagwan,Bernard A. Fox,Richard G. Vile,Hugh Mostafid,Darren R. Shafren,Hardev Pandha	2019	97
7	Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies Hanni Uusi-Kerttula,James A. Davies,Jill Thompson,Phonphimon Wongthida,Laura Evgin,Kevin G. Shim,Angela C. Bradshaw,Alexander T. Baker,P.J. Rizkallah,Robin L. Jones,Louise Hanna,Emma Hudson,Richard G. Vile,John Chester,Alan L. Parker	2018	38
8	Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy Robert A. Berkeley,Lynette P. Steele,Aat A. Mulder,Diana J.M. van den Wollenberg,Timothy Kottke,Jill Thompson,Matthew Coffey,Rob C. Hoeben,Richard G. Vile,Alan Melcher,Elizabeth J. Ilett	2018	53
9	Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues Aadil Khan,James Paget,Martin McLaughlin,Joan Kyula,Michelle Wilkinson,Timothy Pencavel,David Mansfield,Victoria Roulstone,Rohit Seth,Martin Halle,Navita Somaiah,Jessica K.R. Boult,Simon P. Robinson,Hardev Pandha,Richard G. Vile,Alan Melcher,Paul A. Harris,Kevin J. Harrington	2018	17
10	Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors Victoria Roulstone,Khurum Khan,Hardev Pandha,Sarah Rudman,Matt Coffey,George M. Gill,Alan Melcher,Richard G. Vile,Kevin J. Harrington,Johann S. de Bono,James Spicer	2014	42
11	Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-cell Transfer Diana M. Rommelfanger,Phonphimon Wongthida,Rosa María Díaz,Karen M. Kaluza,Jill Thompson,Timothy Kottke,Richard G. Vile	2012	44
12	Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies Eleni Karapanagiotou,Victoria Roulstone,Katie Twigger,Mercel Ball,Mary Anne Tanay,Chris Nutting,Kate Newbold,Martin Gore,James Larkin,Konstantinos N. Syrigos,Matt Coffey,Brad Thompson,K.L. Mettinger,Richard G. Vile,Hardev Pandha,Geoff Hall,Alan Melcher,John Chester,Kevin J. Harrington	2012	151
13	Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers Kevin J. Harrington,Eleni Karapanagiotou,Victoria Roulstone,Katie Twigger,Christine L. White,Laura Vidal,Debbie Beirne,Robin Prestwich,Kate Newbold,Merina Ahmed,Khin Thway,Christopher M. Nutting,Matt Coffey,Dean Harris,Richard G. Vile,Hardev Pandha,Johann S. de Bono,Alan Melcher	2010	94
14	Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy Katie Twigger,Laura Vidal,Christine L. White,Johann S. de Bono,Shreerang Bhide,Matt Coffey,Brad Thompson,Richard G. Vile,Lucy Heinemann,Hardev Pandha,Fiona Errington‐Mais,Alan Melcher,Kevin J. Harrington	2008	88
15	Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors Mohan Hingorani,Christine L. White,Andrew Merron,Inge Peerlinck,Martin Gore,Andrew Slade,Simon D. Scott,Christopher M. Nutting,Hardev Pandha,Alan Melcher,Richard G. Vile,Georges Vassaux,Kevin J. Harrington	2008	20
16	Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy Mohan Hingorani,Christine L. White,Shane Zaidi,Andrew Merron,Inge Peerlinck,Martin Gore,Christopher M. Nutting,Hardev Pandha,Alan Melcher,Richard G. Vile,Georges Vassaux,Kevin J. Harrington	2008	29
17	Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma Fiona Errington‐Mais,Charles L. White,Katie Twigger,Ailsa Rose,Karen J. Scott,Lynette P. Steele,Elizabeth J. Ilett,Robin Prestwich,H S Pandha,Matthew Coffey,Peter J. Selby,Richard G. Vile,Kevin J. Harrington,Alan Melcher	2008	86
18	The Sodium Iodide Symporter and Its Potential Role in Cancer Therapy Christine Spitzweg,Kevin J. Harrington,LORI A. PINKE,Richard G. Vile,John C. Morris	2001	116
19	Cancer metastasis : from mechanisms to therapies Richard G. Vile	1995	7
20	Introduction to the molecular genetics of cancer Richard G. Vile	1992	4

About Richard G. Vile

Richard G. Vile is a scholar working on Genetics, Biotechnology and Immunology, having authored 278 papers that have together received 13.7k indexed citations. Recurring topics across this work include Virus-based gene therapy research (189 papers), CAR-T cell therapy research (102 papers), Immunotherapy and Immune Responses (78 papers), RNA Interference and Gene Delivery (53 papers), Viral gastroenteritis research and epidemiology (44 papers), Cancer Research and Treatments (43 papers), Viral Infectious Diseases and Gene Expression in Insects (31 papers) and CRISPR and Genetic Engineering (21 papers). The work is most often cited by research in Genetics (8.2k citations), Oncology (6.0k citations) and Biotechnology (1.9k citations). Richard G. Vile has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Alan Melcher, Kevin J. Harrington, Hardev Pandha, Rosa María Díaz, Ian R. Hart, Jill Thompson, Timothy Kottke, Stephen J. Russell, Peter J. Selby and Fiona Errington‐Mais.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact